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Receptor tyrosine kinaseTumor progression can be understood as a collaborative effort of mutations and growth factors,
which propels cell proliferation and matrix invasion, and also enables evasion of drug-induced
apoptosis. Concentrating on EGFR, we discuss downstream signaling and the initiation of transcrip-
tional events in response to growth factors. Speciﬁcally, we portray a wave-like program, which
initiates by rapid disappearance of two-dozen microRNAs, followed by an abrupt rise of immediate
early genes (IEGs), relatively short transcripts encoding transcriptional regulators. Concurrent with
the fall of IEGs, some 30–60 min after stimulation, a larger group, the delayed early genes, is up-
regulated and its own fall overlaps the rise of the ﬁnal wave of late response genes. This late wave
persists and determines long-term phenotype acquisition, such as invasiveness. Key regulatory steps
in the orderly response to growth factors provide a trove of potential oncogenes and tumor
suppressors.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Beyond deep understanding of mechanisms underlying tumor
initiation and progression, contemporary cancer research ulti-
mately strives to develop more efﬁcacious and selective anti-tumor
drugs. In the last decade, this avenue of intense research has been
inspired by the ‘oncogene addiction’ theory [1]. Accordingly, can-
cers that contain multiple genetic and chromosomal abnormalities
are dependent on or ‘addicted’ to one or a few genes for mainte-
nance of the malignant phenotype. Thus, reversal of only one or
a few of these abnormalities can inhibit cancer cell growth and
translate to improved survival rates. An example is provided by
the multiple mutant forms of the epidermal growth factor receptor
(EGFR) in lung tumors. Low molecular weight inhibitors of the
EGFR’s kinase effectively inhibit lung tumors when they express
one of the mutant, constitutively active forms of EGFR [2]. Another
‘addiction’ might be exempliﬁed by breast cancers that overex-
press HER2, a kin of EGFR, which are effectively controlled by a
monoclonal anti-HER2 antibody [3]. While cancer genome
sequencing initiatives continue to identify more mutant forms
and candidates for targeted therapies, the remarkable multiplicity
of mutations in solid tumors [4], along with inherent adaptive
mechanisms that lead to patient resistance [5], set formidable
limits to the ‘oncogene addiction’ strategy.It is worthwhile noting that several, rather effective cancer drugs
target non-mutated cellular components. They include the estrogen
receptor in breast cancer, the microtubule network in a variety of
tumors, and the vascular endothelial growth factor (VEGF) in colo-
rectal and other cancers.Moreover, anti-EGFR antibodies effectively
inhibit colorectal tumors despite the fact that EGFR in these malig-
nancies is not usually ampliﬁed or mutated. Interestingly, the pres-
ence of amphiregulin and epiregulin, two ligands of EGFR, in
colorectal tumors predicts response to anti-EGFR antibodies [6].
This suggests that the therapeutic antibody achieves impact by
blocking autocrine or paracrine, stroma-mediated loops involving
EGFR and one of its seven ligands. Consistent with this interpreta-
tion, growth factors play essential roles in most phases of tumor
progression, including clonal ﬁxation of oncogenic mutations,
recruitment of blood and lymph vessels to the growing tumor and
enhancing dissemination of tumor cells, leading to colonization of
distant organs (metastasis) [7]. For example, an in vivo genetic
screen for genes that enhance metastasis of breast cancer to lungs
identiﬁed two ligands of EGFR [8].
Another, very important contribution of growth factors to
tumor progression entails chemotherapy- and radiotherapy-
induced autocrine loops that permit drug resistance. For example,
by generating cisplatin-resistant MCF-7 cells, it was found that
drug resistance associates with increased EGFR phosphorylation,
high levels of AKT1 activity, inactivation of the p53 pathway and
up-regulation of amphiregulin expression [9]. Moreover, knock-
down of amphiregulin expression by speciﬁc short interfering
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type. In conclusion, in-depth understanding of the roles played by
the stroma and growth factors in tumor progression might identify
novel candidates for therapy and for combination treatments
aimed at delaying the onset of resistance to drugs. Driven by this
motivation, our mini-review highlights cytoplasmic and nuclear
actions of growth factors, with an emphasis on transcriptional
regulation by EGFR, a relatively well-understood growth factor
receptor system.
2. Cytoplasmic signaling pathways activated by growth factors
(see Fig. 1)
Growth factors bind to and activate receptors at the plasma
membrane [31]. In the case of EGFR, receptor activation upon
ligand binding involves formation of homo- and hetero- dimers
between EGFR and the other members of the ERBB family. Follow-
ing ligand-induced dimerization, EGFR family members phosphor-
ylate each other to induce full activation of their kinase domains.
Other receptor tyrosine kinases (RTKs) have slightly different
mechanisms of activation, but the end result is the activation of
their intracellular tyrosine kinase domain. The main substrate of
the EGFR kinase is itself; it phosphorylates a series of tyrosines
in a long and probably unstructured carboxyl-terminal tail extend-
ing past the kinase domain. Other RTKs, however, such as the insu-
lin and the insulin-like growth factor 1 (IGF1) receptors recruit andFig. 1. Receptor-mediated signaling and the initiation of transcriptional regulation. Recep
pathways to drive changes in the transcription of speciﬁc RNAs. Adapters (yellow), kin
(encircled P letters) on the activated RTK, and then stimulate particular downstream p
activated to cleave the membrane lipid phosphatidylinositol 4,5-bisphosphate, PIP2, i
culminates in changes in transcription factor (TF) activity, leading to changes in RNA expr
identity of the RTK. Also shown is the negative regulator CBL, which binds to phosphoryla
negative regulators such as MIG6 are not shown.extensively phosphorylate adapter molecules such as IRS, GAB and
FRS. In either case the phosphotyrosines serve as a platform for the
recruitment of downstream signaling complexes [11].
Major pathways downstream of EGFR and RTK activation in
general include the mitogen-activated protein kinase (MAPK) and
the phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT)
routes [12]. EGFR carboxyl-terminal phosphotyrosines recruit
upstream components of the MAPK/ERK pathway, such as Grb2
and Shc [13]. These adaptors bind to the phosphorylated EGFR
and recruit SOS. SOS exchanges GDP for GTP in Ras to activate
Ras, and active Ras then binds to and allosterically activates the
Raf kinase. Raf is the ﬁrst member of a cascade of three kinases
in the MAPK pathway, with Raf activating MEK and MEK activating
the terminal MAPK, Erk [14]. RTK activation of the PI3K pathway
begins by recruitment of a class I PI3K to phosphotyrosines gener-
ated by the activated receptor [15]. PI3K phosphorylates the
relatively abundant phosphoinositide, phosphatidylinositol
4,5-bisphosphate (also known as PI(4,5)P2 or simply PIP2) to gener-
ate PI(3,4,5)P3 (also referred to as PIP3). PIP3 recruits the Akt kinase
to the membrane, where it is activated by phosphorylation by
PDK1 and the mTOR complex 2, mTORC2 [16]. Akt itself phosphor-
ylates several substrates that inhibit apoptosis, including BAD, the
p53 regulator MDM2 and members of the FoxO family of transcrip-
tion factors. The other major role of Akt is to activate mTORC1
through a series of biochemical steps beginning with the phos-
phorylation of TSC2 in the TSC1/TSC2 complex. Phosphorylationtor tyrosine kinases (RTKs), activated by growth factors (GFs) signal through several
ases (green) and other signaling proteins (gray) bind to phosphorylated tyrosines
athways. For instance, upon binding to phosphotyrosine, phospholipase C, PLC, is
nto inositol 1,4,5-trisphosphate, IP3, and diacylglycerol, DAG. Pathway activation
ession. The extent of activation of each of these pathways will vary depending on the
ted tyrosines and ubiquitinates the RTK driving its internalization. Other RTK speciﬁc
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GTP bound form, Rheb is an activator of mTORC1. The net result is
that mTORC1 is activated by Akt. mTORC1 regulates protein trans-
lation and cholesterol biosynthesis, thereby providing protein and
lipid material to cells upon growth factor stimulation [17].
3. Negative regulation of growth factor signaling
Negative regulation of growth factor signaling begins immedi-
ately after receptor activation. In the case of EGFR the biochemical
steps are especially well characterized and begin with the
neddylation and subsequent ubiquitination of EGFR by c-Cbl [18].
Ubiquitinated EGFR is a substrate for internalization. Upon inter-
nalization, EGFR can be degraded by sorting to the multi-vesicular
body, or deubiquitinated and then recycled back to the plasma
membrane. Surprisingly the balance between degradation and
recycling is inﬂuenced by EGFR ligands, with EGF primarily driving
degradation and TGF-a primarily leading to recycling [19,20]. The
weaker afﬁnity and pH sensitive binding of TGF-a to EGFR allows it
to unbind, as the early endocytic compartment is acidiﬁed.
Unbinding then changes the conformation of EGFR, and routes it
for recycling, presumably by encouraging its de-ubiquitination. In
contrast, EGF binds very tightly to EGFR and is not released in
the acidic environment of the endosome. Hence, EGFR bound to
EGF is not de-ubiquitinated and therefore continues down the
endocytic path to ﬁnal degradation in the lysosome. The differen-
tial ability of TGF-a and EGF to drive EGFR degradation appears
to account for the apparent paradox that the tighter binding ligand,
EGF, is less powerful in inducing a transformed phenotype than the
looser binding ligand, TGF-a.
Another important translocation event in growth factor signal-
ing is movement of proteins into or out of the nucleus. One of the
major mechanisms to regulate transcription factors is by facilitat-
ing or allowing their access to the nucleus. For instance some
MAPK substrates, including the ETS family member ERF, depart
from the nucleus upon phosphorylation [21]. Similarly the FoxO
transcription factors, which as mentioned above, are substrates
for Akt, also leave the nucleus and therefore become inactive as
transcription factors upon phosphorylation [22]. Even MAPK itself
translocates into the nucleus upon activation, to gain better access
to nuclear localized transcription factors [23]. In this way, MAPK
enters the nucleus to phosphorylate and exclude some transcrip-
tion factors from the nucleus, while at the same time activating
other transcription factors, such as AP-1, which require phosphor-
ylation to gain activity as transcription factors.
4. Transcriptional responses to growth factor signaling
(see Fig. 2)
A major output of activated MAPK signaling is changes in the
activity of transcription factors. Most of the changes in transcrip-
tion factor activity are probably due to phosphorylation, but other
post-translational modiﬁcations such as ubiquitination, methyla-
tion and acetylation may also be involved. Some transcription fac-
tors, such Elk-1, a member of the ETS group of transcription
factors, are directly phosphorylated by MAPK [24], whereas other
transcription factors such as CREB are phosphorylated by kinases
downstream of MAPK, in this case p90RSK [25]. In still other
instances, parallel pathways downstream of receptor activation
phosphorylate transcription factors, such as Stat [26]. The exact
complement of transcription factors activated by post-translational
modiﬁcations upon growth factor signaling is still an open research
question, but the large changes in transcription that are observed
upon growth factor activation, discussed below, suggest that
multiple transcription factors are probably involved.In the case of EGF, the transcriptional changes upon EGFR acti-
vation are particularly well understood. The expression of approx-
imately 1000 genes is affected by EGF stimulation of epithelial
cells, with activation more common than inhibition by approxi-
mately a 4:1 ratio [27]. Interestingly, however, transcriptional
changes stimulated by steroid hormones such as the glucocorti-
coids, do not show such a strong bias towards activation over
repression [28,29]. Because of the bias for gene activation by RTKs,
much more research has focused on the mechanism and conse-
quences of gene activation downstream of RTKs than on gene
repression.
About 5–10 min after the activation of an RTK, while signaling
continues to evolve in the cytoplasm and at the plasma membrane,
the ﬁrst signals reach the nucleus and begin to affect transcription
[30,31]. The ﬁrst genes activated by a growth factor are typically
seen to accumulate beginning approximately 20 min after the
stimulus. These early genes, called immediate early genes or IEGs,
usually rise rapidly in the levels of their mRNA and then shortly
after rising they quickly fall, usually peaking within the ﬁrst hour
after the stimulus (see Fig. 2). Following the wave of IEGs, another
set of genes, called the delayed early genes or DEGs, are activated
and like the IEGs they also rise and fall, however the peak of DEG
expression is usually seen approximately 2 h after the stimulus.
Finally, approximately 2.5 h after stimulation, a third set of genes
we will call late response genes, or LRGs, begins to rise. Unlike
the IEGs and the DEGs, the LRGs do not drop in expression as long
as the stimulus is maintained, but instead reach a steady state level
of expression between 4 and 8 h after the stimulus [10].
The rise and fall of each wave intuitively suggests that each
wave is inducing the next one, and until recently this has been
the main mechanistic interpretation. Under this classical view
the IEGs serve as transcription factors for the DEGs. The DEGs then
serve to inactivate the IEGs while also signaling forward to the
LRGs. In contrast to this conventional view of each wave activating
the next, new evidence in a variety of systems suggests that some
DEGs and LRGs are transcribed very soon after stimulation but
remain unprocessed, in particular un-spliced, and unprepared for
translation until much later times. In the following section we will
discuss the waves of gene expression in more detail in the context
of the conventional view that each wave of transcription triggers
the next one. Then we will examine a new emerging model from
several cellular systems suggesting that many LRGs are actually
primary transcripts. We will close by exemplifying how a long-
term phenotype, cell migration, is regulated by transcription. Note
that some publications refer to LRGs as secondary response genes
(or SRGs), but we will refer to the third wave of genes as LRGs, late
response genes, since we wish to present evidence that many of
these genes are in fact primary transcripts.
5. The fast rise and fall of IEGs
Approximately 10–20 min after stimulation with a growth fac-
tor, IEGs begin to be transcribed. Because many IEGs, such as c-Fos,
c-Jun and c-Myc, are proto-oncogenes, their transcription has been
heavily studied [32]. Several unique features of IEGs facilitate their
rapid increase in transcription. Beginning at the chromatin level,
IEGs maintain an open permissive chromatin structure even in
the absence of stimulation [31,33]. This open chromatin is reﬂected
in the presence of CpG islands and strong TATA boxes at the 50 end
of IEGs. The presence of strong CpG islands at the start of IEGs sug-
gests that IEGs probably bind RNA Pol II constitutively but in a
paused or stalled state and indeed this is often found to be the case
experimentally [31]. At some IEGs, however, evidence suggests
that Pol II is actively transcribing a low level of full-length
transcripts in the absence of growth factor stimulation, but that
Fig. 2. The timeline of transcription regulation by growth factors. Transcriptional waves downstream of an RTK stimulus, like EGFR ligands, alternate between putative proto-
oncogenes and candidate tumor suppressors [10]. Immediately after the stimulus a group of microRNAs (miRs) are down-regulated. These immediately down-regulated miRs
(ID-miRs) primarily target the immediate-early genes (IEGs) and are enriched for miRs of tumor suppressor function [36]. Examples include mir-101 [74], miR-320 [75], miR-
370 [76] and miR-663 [77]. Notably, however, some ID-miRs seem to play dual roles as both tumor suppressors and oncogenes depending on the cancer context. Released
from inhibition by the destruction of the ID-miRs, the IEGs, encoding oncogenic transcription factors like EGR1 [78], rise and fall within the ﬁrst hour post stimulus [32].
Trailing the IEGs, the delayed-early genes (DEGs) encode many candidate tumor suppressors, whose role in the transcriptional program is to inhibit growth factor signaling
[30]. For example, the group of DEGs includes DUSPs [79], KLF6 [80], ZFP36 [40] and MIG-6 [81,82]. Culminating the RTK stimulated gene expression program, late-response
genes are up- and down-regulated, driving phenotypic changes due to growth factor signaling [51,83]. Up-regulated late response genes (UR-LRGs), are enriched for putative
proto-oncogenes. For example, some highly mitogenic and motogenic RTK ligands and inﬂammatory cytokines like HB-EGF [84] and IL8 [85], respectively, rise soon after the
stimulus, but unlike the IEGs, they persist. Other positive regulators of tumor progression, like matrix metalloproteinases, MMPs [86], and CTEN [68], are also included in the
UR-LRGs group. Reciprocally, the stably down-regulated late response genes (DR-LRGs) might act as tumor suppressors in speciﬁc cellular contexts. This group includes cell
cycle regulators like p27-Kip1 and p53, as well as EHF/ESE3, a putative suppressor of prostate cancer [87].
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and the transcripts are quickly degraded [34]. The binding of Pol
II, promoted by the strong TATA boxes, prevents CpG DNA methyl-
ation. Since DNA methylation is mutagenic on the evolutionary
time scale, CpGs are only allowed to accumulate at sites in the gen-
ome where methylation is prevented, such as the 50 end of genes
that constitutively bind RNA Pol II [35]. Genes that constitutively
bind RNA Pol II can be roughly divided into house keeping genes
that are constitutively transcribed in most cells, and gene such as
IEGs. Although IEGs are not constitutively transcribed, due to their
strong TATA boxes and other motifs important for recruiting the
transcription initiation machinery, they bind Pol II all the time in
a poised state ready for rapid transcription.
IEGs are poised for production but because of their power as
oncogenes, there needs to be a mechanism to suppress spurious
transcripts. In the case of signaling by EGFR and probably by other
RTKs, a class of miRs suppresses the IEGs prior to growth factor
stimulus [36]. Upon stimulation however, to facilitate the rapid
rise of the IEGs, the concentration of the IEG-targeting miRs (called
immediately down-regulated miRs, or ID-miRs) drops quickly,
within the ﬁrst few minutes after stimulation. Because the drop
in the ID-miRs is so quick, their fall is likely due to degradation
rather than reduced transcription, although the exact mechanism
degrading the ID-miRs is still unclear.Also helping to maintain low levels of IEG mRNA prior to RTK
stimulation is the inherent instability of IEG mRNA [37]. Any IEG
mRNA that is accidently produced will be quickly degraded. The
instability of IEG mRNA also facilitates their rapid rise because it
allows a high rate of mRNA production to be coupled to rapidly
reaching a moderate steady state level of mRNA. Without rapid
degradation, a high production rate of mRNA would instead lead
to the slow accumulation of a massive amount of mRNA. To mini-
mize the waste of resources associated with rapidly synthesizing
and degrading IEG mRNA, most IEGs are very short, only a few
kb long, and unlike most genes, many have few or no introns. Being
short also minimizes the time required to transcribe the IEGs,
allowing their mRNA to be accessible for translation with a mini-
mal delay following the induction of their transcription.
Within their rise, the IEGs encode their own demise; the tran-
sient rise and fall of many IEGs is nearly complete within the ﬁrst
hour after stimulation [30]. IEGs rapidly fall because their tran-
scription is stopped and their mRNA is further destabilized [32].
Some IEGs negatively regulate their own promoters forming a sim-
ple network motif termed negative autoregulation, or NAR. In the
absence of other inﬂuences however, NAR is predicted to lead to
a rapid rise to a steady state [38]. Other factors beyond simple
NARmust therefore be required to shape the IEG mRNA proﬁle into
a short pulse. One such factor is the mRNA binding protein ZFP36,
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to and destabilizes mRNAs containing AU-rich elements (AREs)
such as the IEG mRNAs [39]. Recently, consistent with its role in
destabilizing potentially oncogenic IEGs, ZFP36 has emerged as a
potential tumor suppressor in a diverse set of cancers, including
glioma [40–43].
6. DEGs and LRGs: calming down and looking forward
Many of the IEGs are transcription factors, and according to the
classical model of growth factor-induced transcription, their activ-
ity is responsible for much of the induction of DEGs. Unlike the
IEGs, which are mainly transcriptional activators, the DEGs contain
a preponderance of negative regulators, of both transcription and
signaling, such as MAPK phosphatases, whose induction after the
IEGs further shapes the IEG proﬁle into a tight pulse. Although
DEGs share many characteristics with IEGs, they are not tuned
for the extremely rapid rise and fall of the IEGs. Following RTK
stimulation they rise more slowly than IEGs, and often reach a
broad peak in expression around 2 h post stimulation, before
slowly falling between 2 and 3 h after the stimulus. DEG mRNA
is more stable than IEG, but less stable than other mRNAs [37].
DEGs mostly possess CpG islands at their 50 end and, like IEGs,
are occupied by poised RNA polymerase II, but at generally lower
levels than the IEGs. Unlike the IEGs however, DEGs show no
enrichment for strong TATA boxes and have a similar length and
quantity of introns to the genome at large [31]. In summary DEGs
have genomic characteristics consistent with their ability to rise
and fall after RTK stimulus without the level of instability and
other properties required by the IEGs for extremely rapid rise
and fall.
Many DEGs negatively regulate the growth factor response [10].
Some DEGs directly inhibit the transcription factors that activate
the IEGs. For instance, the Id subfamily of helix-loop-helix proteins
inhibits TCF transcription factors such as Elk-1, which are phos-
phorylated by MAPK and activate IEGs. Another level of transcrip-
tional repression is exempliﬁed by the DEGs FOSL1 and JUNB,
which inhibit the activity of the IEGs FOS and JUN, respectively,
in AP-1 complexes. In these ways, DEG transcription factors repress
the transcription of IEGs, as well as directly antagonize the IEGs
themselves. The other major mode of negative regulation by the
DEGs is to inhibit the signaling cascades, especially MAPK, down-
stream of RTK activation. Examples of DEG negative regulators of
cell signaling include Mig6/ERFFI1, and members of the dual spec-
iﬁcity phosphatase family, DUSPs. Mig6 is a direct inhibitor of EGFR
itself [44,45], while DUSPs are specialized phosphatases that can
dephosphorylate and thereby inactivate MAPKs on both threonine
and tyrosine phosphorylation sites [46]. Consistent with their role
in antagonizing IEG signaling downstream of RTKs, many DEGs,
such as Mig-6 are tumor suppressors (see Fig. 2). After the IEGs
and cell signaling have been repressed, several DEGs continue to
persist for an extended period of time, suggesting that they impose
a refractory period during which subsequent RTK activation and
IEG transcription will be impossible. The presence of a refractory
period after growth factor signaling indicates that oscillations
might occur in the presence of a sustained source of growth factor
or in the case of an autocrine loops.
7. Primary late response genes (PLRGs)
The ﬁnal wave of induced transcriptional changes, the late-
response genes (LRGs), follows the DEG wave. LRGs rise slowly
beginning around 2 h after the stimulus and unlike the IEGs and
DEGs, LRGs continue to rise until they reach a steady state plateau
level of mRNA. Also unlike IEGs and DEGs, LRG mRNAs are verystable [37] with a stability similar to that of un-induced mRNAs.
As we discuss in the end of this mini-review, the stable expression
of LRGs is thought to be responsible for phenotypic changes such as
cell migration [47]. To further stabilize the post-stimulus pheno-
type, some LRGs are RTK ligands that will continue to activate
the RTK through an autocrine mechanism, even if the original
stimulus wanes.
Because their appearance is delayed by several hours following
RTK stimulation, it was initially assumed that late response genes,
LRGs, would all be secondary response genes, SRGs. The delayed
appearance of LRGs was assumed to be due to the time required
for a transcriptional network downstream of the initial RTK stimu-
lus to produce new activating transcription factors to initiate tran-
scription of the LRGs. Supporting this intuition, when the ﬁrst LRGs
were discovered they were all found to be SRGs, meaning that their
transcription was strictly inhibited by CHX, a protein synthesis
inhibitor [48] (see Box 1). Subsequent genome wide analysis of
transcription in the presence of CHX, however, found that many
LRGs are actually PRGs, meaning that they are relatively insensitive
to CHX [31]. Understanding the delayed appearance of these genes
presents a conundrum because it is unclear how a cell can delay
the appearance of an mRNA without making the RNA dependent
on preceding slow transcriptional steps. Stated another way, there
is no clear way to explain the fact that transcription initiation of
some LRGs apparently begins shortly after the RTK stimulation,
at the same time as the IEGs, yet the mRNA for these genes does
not appear for several hours.Box 1. Cycloheximide differentiates primary from second-
ary inducible transcripts.
Cycloheximide (CHX), which blocks protein synthesis from
mRNA, has been an essential tool for understanding stimu-
lus-induced changes in gene expression. A characteristic fea-
ture of the IEGs, which was recognized early on [32,70], is that
in the presence of CHX, rather than rising and quickly falling
after the stimulus, IEG mRNAs accumulate to higher than
normal levels and remain high without falling. Degradation
of IEG mRNAs requires active protein synthesis because the
act of translation shortens the polyA tail of IEG mRNAs, even-
tually leading to their degradation [71]. The translation
dependent removal of IEG polyA requires AU-rich elements
present in the IEGs [72], probably through a mechanism
involving ZFP36 [73]. Since the degradation of IEGs requires
active translation, in the presence of CHX, IEGs accumulate
to high levels and persist, rather than showing a short pulse.
In addition to uncovering the translation-dependent deg-
radation of IEG mRNAs, CHX is also valuable because it can
divide stimulus-responsive genes into primary responsive
genes (PRGs) and secondary responsive genes (SRGs) [48].
IEGs are a subset of PRGs, whose mRNA accumulation is
not blocked by CHX, because they do not require the synthe-
sis of new proteins to induce their expression. Activation of
pre-existing transcription factors downstream of RTK activa-
tion is all that is required for PRG activation. Unlike PRGs,
SRGs require new protein synthesis for their induction fol-
lowing RTK stimulation. The conventional interpretation for
their CHX sensitivity is that SRGs are activated by transcrip-
tion factors, which do not exist in the cell prior to stimulation
and these transcription factors must be translated and prob-
ably transcribed in order to activate the SRGs. Notably, other
interpretations of CHX sensitivity are possible because the
factor(s) that must be translated to allow SRG expression
could be involved in another step of mRNA production than
transcription initiation. As discussed in the main text, for
some LRGs, the splicing step in RNA processing seems to
be a regulated step and this step could theoretically be CHX
sensitive if it relies on a newly translated factor.
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exclusive mechanisms may be capable of explaining the late
appearance of some PRGs. Danko et al. measured the transcription
rate in estrogen-stimulated cells using global run-on sequencing,
GRO-seq, and found that transcription rates vary by almost 10-fold
between different genes, ranging from 0.4 to 4 kb/min [49]. In
addition, the authors showed that the transcription rate at individ-
ual genes can vary by as much as 4-fold between different cells and
different stimuli. Since the median length of a human gene is about
20 kb [50], for most genes any transcription rate faster than about
1 kb/min should be fast enough to allow for fairly rapid accumula-
tion of mRNA following a stimulus, but for the minority of human
genes longer than 100 kb, including JARID2 and NFKB1, a transcrip-
tion rate of 1 kb/min or less would severely limit the speed of their
transcriptional response. Interestingly, many genes, such as EGFR,
harbor alternate promoters such that a cell can choose to produce
a transcript with a greatly extended ﬁrst intron from a promoter
far upstream, or to produce a short transcript coding for a very sim-
ilar protein product, differing perhaps only in the ﬁrst exon. One
attractive explanation for the common genomic feature of alterna-
tive promoters differing only by a long ﬁrst intron is that the length
RNA polymerase II must travel when transcribing a gene can be
varied by the cell to change the timing of a transcriptional
response.
Although some PLRGs like vinculin are quite long at 125 kb,
other PLRGs such as laminin gamma 2 (60 kb), Dickkopf-related
protein 1 (3.4 kb), and cyclin D1 (13 kb) are not especially long,
suggesting that gene length is not the primary factor leading to
delayed expression of PLRGs. RNA splicing has recently emerged
as a regulated step in the production of stimulus responsive genes
that can help explain the origin of PLRGs. Hao and Baltimore [37]
measured the kinetics of pre-mRNA and mRNA production in
response to TNF-induced transcription and found that the tran-
scription of the LRGs they examined began immediately following
the stimulus, at the same time as IEG transcription in response to
TNF. Although TNF-induced transcription of LRGs began a few min-
utes after the stimulus, unlike the IEGs, whose transcription began
at the same time, spliced mRNA for the LRGs did not appear till
much later. Like Hao and Baltimore, Zeisel et al. also examined
stimulus-induced changes in mRNA and pre-mRNA following EGF
stimulation [51], however instead of PCR, their primary assay
was based on microarray measurements of intronic and exonic
sequences, allowing genome wide estimation of mRNA and pre-
mRNA levels. Looking genome wide, Zeisel et al. found many
instances where un-spliced pre-mRNA accumulated long before
the appearance of the respective spliced mRNAs. The magnitude
of time delay seen by Zeisel et al. between pre-mRNA and mRNA
accumulation was quite surprising. For instance, laminin gamma
2 pre-mRNA was seen to accumulate in the ﬁrst hour following
EGF stimulation, while the corresponding spliced mRNA did not
rise until 4–8 h after the stimulus. Using LPS and Lipid-A as stimuli,
Bhatt et al. [52] isolated chromatin associated RNA, to ﬁnd that
immediately following stimulation, un-spliced transcripts accumu-
late and remain associated with the chromatin. Subsequently after
a delay of between 10 and 30 min, spliced mRNAs appeared in the
cytoplasm. Altogether, these studies suggest that regulation of RNA
splicing may be an important control point in determining the time
course of gene expression.8. Transcription-mediated regulation of cell migration
by growth factors
To exemplify the ability of cytoplasmic and nuclear events to
collaboratively initiate long lasting, delayed responses to growth
factors, we focus below on EGF-regulated migration of epithelialcells. To sustain a migratory phenotype, cells apply both early tran-
scription-independent events, and transcriptional switches. Sev-
eral cytoplasmic pathways are rapidly engaged by growth factor-
stimulated migrating cells. For example, phospholipase C (PLC)
gamma, the enzyme that hydrolyzes PIP2, is rapidly phosphory-
lated and activated by EGFR, and this is essential for the induction
of cellular motility [53]. The underlying mechanism entails activa-
tion of PIP2-inhibited actin-modifying proteins, such as gelsolin
[54] and coﬁlin [55]. Likewise, phosphoinisitides generated by
PI3K, speciﬁcally PI(3,4,5)P3 [56] and its dephosphorylated product
PI(3,4)P2 [57], establish signposts essential for invadopodia
formation at the ventral side of migrating cells [58]. In addition,
activation of PI3K and Src by EGF leads to stimulation of
RAC1, which enhances cell migration [59]. In parallel, active ERK
regulates membrane protrusions [60] and localizes to the leading
edge, where it phosphorylates cortactin and activates the ARP2/3
actin nucleator [61]. In addition, ERK activates the myosin light
chain kinase (MLCK), which induces phosphorylation of myosin
and leads to actin polymerization and membrane protrusion
[62].
These and additional cytoplasmic processes precede transcrip-
tion-controlled molecular switches, which convert a polarized epi-
thelium to a collection of motile cells [63,64]. This process of
epithelial-to-mesenchymal transition (EMT) involves loss of epi-
thelial markers like E-cadherin, and gain of mesenchymal markers,
such as N-cadherin, ﬁbronectin and several transcription factors,
including Ets-1 and snail [64]. Loss of E-cadherin, the major
hallmark of EMT, is often coupled to up-regulation of another cal-
cium-dependent cell adhesion molecule, N-cadherin [65]. For
example, cells stimulated with TGF-beta show increased N-cad-
herin expression and loss of junctional E-cadherin [66]. This switch
is directly regulated by a group of repressors, like snail and the ZEB
proteins, and indirectly by twist, goosecoid, E2.2 and FOXC2 [67].
Stimulation of mammary cells with EGF activates another switch,
namely transcriptional up-regulation of CTEN (also called tensin-
4) and a concomitant down-regulation of tensin 3 [68]. This reci-
procal switch likely enables CTEN to displace tensins from the
cytoplasmic tail of integrins thereby disassembling focal adhesions
and promoting cell migration. By contrasting a signaling cascade
leading to cell migration (stimulated by EGF) and a distinct
pathway culminating in cell proliferation (stimulated by serum),
we uncovered another transcriptional switch, which involves
Erk-mediated phosphorylation of ERF, an ETS family member,
translocation of the latter out of the nucleus and transcription of
Egr1, an IEG that regulates several target genes essential for cell
migration (e.g., PLAUR, SerpinB2 and the parathyroid hormone-
related protein, PTHrP) [21]. In addition, Egr1 also regulates several
inhibitors of cell migration, such as the MAPK phosphatase DUSP4,
EGR3 and the repressor BHLHB2, which likely represents homeo-
static regulation of cell migration by IEGs like Egr1.
9. Concluding remarks
Although acquired somatic aberrations and multiple growth
factors propel tumor progression, the latter, along with other
tumor–stroma interactions offer genetically more stable targets
for cancer therapy. Mounting a strategy able to intercept growth
factor action entails in-depth understanding of molecular mecha-
nisms underlying not only signal transduction but also organiza-
tion of cellular networks and control circuitries. By highlighting
time series analyses and focusing on the EGFR pathway, we
portrayed a highly dynamic order of biochemical events, which ini-
tiates at the plasma membrane and culminates in the nucleus.
These transcriptional steps are very logical, highly reproducible
and common to multiple growth factors, but they appear to be dis-
torted in tumors. For example, the well-characterized IEG group of
M.E. Feldman, Y. Yarden / FEBS Letters 588 (2014) 2407–2414 2413inducible transcription factors has served as a rich source of proto-
oncogenes, counterparts of retrovirus-encoded cancer promoting
genes [69]. Conversely, the newly discovered group of ID-miRs is
commonly down-regulated in mammary tumors, as compared to
the surrounding normal epithelium [36]. Similarly, the group of
DEGs, which trails the IEGs, is signiﬁcantly down-regulated in dif-
ferent tumor types [30], as if some human tumors are locked in a
growth factor stimulated ‘active’ state, which would normally
return to a basal level soon after stimulation. The ﬁnal and most
persistent wave of growth factor inducible genes, might be also
the most divergent one, as it includes both oncogenic and tumor
suppressor genes and reﬂects long term phenotypic alterations in
cell proliferation, migration and differentiation. Studying each of
these genes and understanding their group dynamics might spear-
head the identiﬁcation of new biomarkers and novel targets for
drug intervention.
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